Evidence map›Paper›PMID 18590527›Full record

ArticleBMC cancer2008

Recurrent and multiple bladder tumors show conserved expression profiles.

David Lindgren, Sigurdur Gudjonsson, Kowan Ja Jee, Fredrik Liedberg, Sonja Aits, Anna Andersson, Gunilla Chebil, Ake Borg, Sakari Knuutila, Thoas Fioretos and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Profiles of urinal exosomal miRNAs derived from bladder cancer.Central European journal of urology · 2024
    Article
  3. Article
  4. The role of WNT signalling in urothelial cell carcinoma.Annals of the Royal College of Surgeons of England · 2015
    Article
  5. Article
  6. Article
  7. Article
  8. Low-grade smooth muscle tumors of the primary and the secondary mullerian system: a proposed concept of multicentricity.International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2012
    Article
  9. Testing clonality of three and more tumors using their loss of heterozygosity profiles.Statistical applications in genetics and molecular biology · 2012
    Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

David LindgrenDepartment of Clinical Genetics, Lund University Hospital, Lund, Sweden. david.lindgren@med.lu.se
Sigurdur Gudjonsson
Kowan Ja Jee
Fredrik Liedberg
Sonja Aits
Anna Andersson
Gunilla Chebil
Ake Borg
Sakari Knuutila
Thoas Fioretos
Wiking Månsson
Mattias Höglund
Lund University · SEUniversity of Helsinki · FIHelsingborgs lasarett · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUrothelial carcinomas originate from the epithelial cells of the inner lining of the bladder and may appear as single or as multiple synchronous tumors. Patients with urothelial carcinomas frequently show recurrences after treatment making follow-up necessary. The leading hypothesis explaining the origin of meta- and synchronous tumors assumes a monoclonal origin. However, the genetic relationship among consecutive tumors has been shown to be complex in as much as the genetic evolution does not adhere to the chronological appearance of the metachronous tumors. Consequently, genetically less evolved tumors may appear chronologically later than genetically related but more evolved tumors.

methodsForty-nine meta- or synchronous urothelial tumors from 22 patients were analyzed using expression profiling, conventional CGH, LOH, and mutation analyses.

resultsWe show by CGH that partial chromosomal losses in the initial tumors may not be present in the recurring tumors, by LOH that different haplotypes may be lost and that detected regions of LOH may be smaller in recurring tumors, and that mutations present in the initial tumor may not be present in the recurring ones. In contrast we show that despite apparent genomic differences, the recurrent and multiple bladder tumors from the same patients display remarkably similar expression profiles.

conclusionOur findings show that even though the vast majority of the analyzed meta- and synchronous tumors from the same patients are not likely to have originated directly from the preceding tumor they still show remarkably similar expressions profiles. The presented data suggests that an expression profile is established early in tumor development and that this profile is stable and maintained in recurring tumors.

Indexed as

Gene Expression ProfilingGene Expression Regulation, NeoplasticCarcinomaCell Transformation, NeoplasticDNA Mutational AnalysisFemaleHumansMaleNeoplasm Recurrence, LocalNeoplasms, Multiple PrimaryNeoplasm StagingOligonucleotide Array Sequence AnalysisPoint MutationReceptor, Fibroblast Growth Factor, Type 3Tumor Suppressor Protein p53Urinary Bladder NeoplasmsFGFR3 protein, humanReceptor, Fibroblast Growth Factor, Type 3TP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID18590527
PMCPMC2483988
OpenAlexW2137202500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.